Kyntra Bio (KYNB) Non Operating Interest Expenses (2014 - 2026)

Kyntra Bio has disclosed Non Operating Interest Expenses across 13 years of filings, most recently posting $2.4 million for Q2 2026.

• In Q2 2026, Non Operating Interest Expenses rose 17.87% year-over-year to $2.4 million; the TTM figure through Jun 2026 stood at $9.3 million (up 8.63% YoY), while the FY2025 annual figure was $8.8 million, up 6.21% from the prior year.
• Non Operating Interest Expenses came in at $2.4 million for Q2 2026 at Kyntra Bio, down from $2.4 million in the prior quarter.
• In the past five years, Non Operating Interest Expenses ranged from a high of $5.0 million in Q3 2023 to a low of -$2.4 million in Q4 2023.
• Average Non Operating Interest Expenses over 5 years is $1.8 million, with a median of $2.2 million recorded in 2024.
• The largest YoY upside for Non Operating Interest Expenses was 5878.57% in 2023 against a maximum downside of 311.71% in 2023.
• Over 5 years, Non Operating Interest Expenses stood at $1.1 million in 2022, then tumbled by 311.71% to -$2.4 million in 2023, then jumped by 193.63% to $2.2 million in 2024, then gained by 8.79% to $2.4 million in 2025, then slipped by 1.86% to $2.4 million in 2026.
• Per Business Quant data, the three most recent Non Operating Interest Expenses figures were $2.4 million in Q2 2026, $2.4 million in Q1 2026, and $2.4 million in Q4 2025.